OrbiMed Raises $3 Billion for Global Healthcare Investments

OrbiMed has successfully raised $3 billion across two new private equity funds focused on global healthcare investments. The capital will be utilized to support life sciences and healthcare businesses, with a particular emphasis on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The two funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, will invest in companies working on groundbreaking medical therapies or healthcare solutions.

AI and biotechnology are key trends shaping OrbiMed's investment strategy. The company expects these investments to help entrepreneurs build leading businesses across global markets, particularly in the face of ongoing advances in healthcare innovation. The firm operates with 20 partners and over 150 professionals, bringing expertise in company incubation, strategy, operations, and finance.

Its team is strategically located in 12 major healthcare markets, allowing OrbiMed to provide capital and operational support to healthcare companies worldwide.

The new fundraising efforts attracted commitments from a diverse range of investors, including institutional investors, foundations, pension funds, sovereign wealth funds, and family offices. OrbiMed's managing partner, Carl Gordon, highlighted the firm's global presence as a crucial factor in identifying opportunities for transformative treatments across both established and emerging markets.

With its expanded capital base and global team, OrbiMed is well-positioned to support the development of sustainable healthcare businesses capable of responding to ongoing changes in AI and biotechnology.